{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:20:25Z","timestamp":1785860425944,"version":"3.56.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1097\/01.jcp.0000219927.49799.c0","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T04:21:08Z","timestamp":1147148468000},"page":"346-347","source":"Crossref","is-referenced-by-count":17,"title":["Combination Therapy of Lamotrigine and Escitalopram May Cause Myoclonus"],"prefix":"10.1097","volume":"26","author":[{"given":"Marcus C.","family":"Rosenhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00023210-200418020-00003","article-title":"Drug-induced myoclonus: frequency, mechanisms and management.","volume":"18","author":"Jimenez-Jimenez","year":"2004","journal-title":"CNS Drugs"},{"key":"R2-25-20210128","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1212\/WNL.58.6.984","article-title":"Multifocal myoclonus due to verapamil overdose.","volume":"58","author":"Vadlamudi","year":"2002","journal-title":"Neurology"},{"key":"R3-25-20210128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00002826-200003000-00005","article-title":"Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases.","volume":"23","author":"Janszky","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"R4-25-20210128","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-2999(98)00955-8","article-title":"Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells.","volume":"367","author":"Hahn","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R5-25-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-0447.1997.tb09933.x","article-title":"Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.","volume":"96","author":"Spigset","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"R6-25-20210128","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, a comparison to R-citalopram.","volume":"29","author":"Von Moltke","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"R7-25-20210128","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome.","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"R8-25-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01271247","article-title":"Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports.","volume":"103","author":"Staedt","year":"1996","journal-title":"J Neural Transm"},{"key":"R9-25-20210128","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/j.1460-9568.2003.03051.x","article-title":"5HT inhibits N-type but not L-type Ca 2+ channels via 5-HT1A receptors in lamprey spinal neurons.","volume":"18","author":"Russell","year":"2003","journal-title":"Eur J Neurosci"},{"key":"R10-25-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0197-0186(01)00088-2","article-title":"Lamotrigine induced selective changes in 5-HT1A receptor mediated response in rat brain.","volume":"40","author":"Vinod","year":"2002","journal-title":"Neurochem Int"},{"issue":"3","key":"R11-25-20210128","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000026538","article-title":"Female genital disorder as adverse symptom of lamotrigine treatment. A serotonergic effect?","volume":"38","author":"Erfurth","year":"1998","journal-title":"Neuropsychobiology"},{"key":"R12-25-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1059-1311(98)80074-5","article-title":"Lamotrigine toxicity secondary to sertraline.","volume":"7","author":"Kaufman","year":"1998","journal-title":"Seizure"},{"key":"R13-25-20210128","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00004714-200304000-00011","article-title":"Antidepressant properties of anticonvulsant drugs for bipolar disorder.","volume":"23","author":"Ernst","year":"2003","journal-title":"J Clin Psychopharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007632-200605151-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:25:02Z","timestamp":1785857102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200606000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000219927.49799.c0","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}